Literature DB >> 9869461

Penetration of piperacillin into the vitreous after intravenous administration.

A Robinet1, M A Le Bot, J Colin, C Riche.   

Abstract

PURPOSE: Penetration of piperacillin into the vitreous cavity after intravenous administration was investigated in humans.
METHODS: Forty-five eyes undergoing vitrectomy between November 1993 and December 1994 were included. Each patient received a single intravenous dose of piperacillin 4 g 2 hours before ocular incision. A 0.2-mL vitreous sample was aspired at the beginning of vitrectomy, a blood sample was obtained, and piperacillin level was assessed.
RESULTS: There were no detectable drug concentrations in 25 eyes. Mean vitreous drug concentration in the remaining evaluable eyes (n = 14) was 2.33 microg/mL (+/-0.76). We divided samples into two groups: 23 uninflamed (Group 1) and 16 inflamed (Group 2) eyes. Mean vitreous drug concentration was 0.42 microg/mL in Group 1 and 4.95 microg/mL in Group 2 (P < 0.2). Piperacillin concentration was higher than the minimum inhibitory concentration for gram-positive bacteria in 13% of uninflamed and 69% of inflamed eyes (P < 0.001).
CONCLUSION: Studies show that intravenously administered piperacillin can penetrate the vitreous cavity in rabbits. Our study suggests that a single dose of piperacillin can produce intravitreal concentrations sufficient to kill gram-positive bacteria in inflamed eyes. The poor intraocular penetration of systemically administered piperacillin in uninflamed eyes raises questions about its usefulness as a prophylactic agent in ophthalmic surgery.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9869461     DOI: 10.1097/00006982-199806000-00006

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  1 in total

1.  Intravenous administration of Penicillin results in therapeutic intravitreal levels in chronic postoperative endophthalmitis.

Authors:  Chloe Thabet; Chloe C C Gottlieb; Bernard R Hurley; Guijun Zhang; Adeel Sherazi; Jonathan B Angel
Journal:  J Ophthalmic Inflamm Infect       Date:  2021-01-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.